SCHEMBL184982

SCHEMBL184982

O=S(=O)(c1cccc(CNCc2ccc(F)cc2)c1)N(Cc1ccc(F)cc1)Cc1cc(Cl)cc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 4/20 0.47
CXCR3 P49682 2/20 0.47
TAS2R14 Q9NYV8 5/20 0.46
BCL2 P10415 1/20 0.46
NR1H2 P55055 2/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
NR1H3 Q13133 1/20 0.45
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CNR1 P21554 1/20 0.44
CNR2 P34972 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL183993 0.86 KCNA5 (0.48) KCNA5CXCR3TAS2R14BCL2NR1H2
SCHEMBL10248389 0.82 KCNA5 (0.49) KCNA5CXCR3TAS2R14BCL2NR1H2
SCHEMBL185297 0.81 NR1H2 (0.50) KCNA5CXCR3TAS2R14BCL2NR1H2
SCHEMBL185080 0.80 BCL2 (0.70) KCNA5TAS2R14BCL2NR1H2NR1H3
SCHEMBL184864 0.80 KCNA5 (0.59) KCNA5CXCR3TAS2R14BCL2NR1H2
SCHEMBL27970526 0.78 BCL2 (0.44) KCNA5CXCR3TAS2R14BCL2NR1H2
SCHEMBL13568197 0.77 BCL2 (0.45) KCNA5CXCR3TAS2R14BCL2NR1H2
SCHEMBL184892 0.75 BCL2 (0.51) BCL2CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL14025639 0.75 TAS2R14 (0.49) CXCR3TAS2R14ALDH1A1CNR2
SCHEMBL13568180 0.74 BCL2 (0.53) KCNA5CXCR3TAS2R14BCL2NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102112445-B Hydroxyphenylsulfonamides as antiapoptotic Bcl inhibitors BRISTOL MYERS SQUIBB CO 2014-06-18 CN disclosed
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
EP-2297103-B1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-01-04 EP disclosed
EP-2297103-B1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-01-04 EP disclosed
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BCL2, BAX, BCL2A1 KCNA5 2772/4885CXCR3 2539/4885TAS2R14 3613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.